Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deoxycytidine/deoxythymidine - Modis Therapeutics

Next Previous
Drug Profile

Deoxycytidine/deoxythymidine - Modis Therapeutics

Alternative Names: dC/dT - Modis Therapeutics; Deoxycytidine/deoxythymidine; Doxecitine/Doxribtimine - UCB; doxTM; MT 1621 - UCB; MT-1621; Thymidine/deoxycytidine - Modis Therapeutics

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University Medical Center; Vall d-Hebron Research Institute
  • Developer Columbia University Medical Center; Modis Therapeutics; Vall d-Hebron Research Institute
  • Class Deoxyribonucleosides; Small molecules
  • Mechanism of Action Deoxyribonucleoside replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Mitochondrial disorders

Most Recent Events

  • 31 Mar 2025 Preregistration for Mitochondrial disorders (In adolescents, In children, In the elderly, In adults) in USA (PO)
  • 31 Mar 2025 Preregistration for Mitochondrial disorders in European Union (PO)
  • 31 Mar 2025 Deoxycytidine/deoxythymidine receives priority review status for Mitochondrial disorders in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top